8-K: Vaxcyte Announces Positive Phase 2 Results for VAX-24 Infant Pneumococcal Vaccine Candidate; Plans Phase 3 Trials

Vaxcyte reports positive topline results from its Phase 2 dose-finding study of VAX-24 in healthy infants, showing a safety profile similar to Prevnar 20 and substantial immune responses.

Summary

• Vaxcyte announced positive topline results from its Phase 2 dose-finding study of VAX-24, a 24-valent pneumococcal conjugate vaccine candidate, in healthy infants.
• The study evaluated the safety, tolerability, and immunogenicity of VAX-24 compared to Prevnar 20 (PCV20).
• VAX-24 was well-tolerated and demonstrated a safety profile similar to PCV20 across all doses studied.
• All VAX-24 doses (Low: 1.1 mcg, Mid: 2.2mcg and Mixed: 2.2mcg/4.4mcg) elicited substantial IgG and OPA immune responses at 1-month post-dose 3.
• The Mid dose met target precedent Phase 2 non-inferiority criteria on relative seroconversion rates for 20 of 24 serotypes overall.
• The Mid dose also met the target Phase 2 IgG Geometric Mean Ratio (GMR) point estimate of >0.63 on 22 of 24 serotypes overall.
• VAX-24 generated robust OPA responses across all serotypes and doses.
• The four serotypes unique to VAX-24 elicited robust immune responses and met all target criteria across all endpoints at all doses evaluated post-dose 3.
• Dose-dependent immune responses were consistently demonstrated, and little to no carrier suppression was observed.
• Interim booster dose IgG data showed robust memory responses across all doses for all serotypes.
• The company has selected the VAX-24 Mid dose (2.2mcg) as the basis for an optimized dose formulation for advancement to a potential infant Phase 3 program.
• The company also announced VAX-XL, its third-generation PCV candidate designed to further expand the spectrum of coverage.
• The company plans to initiate a Phase 3 infant program with either VAX-24 or VAX-31, pending the VAX-31 infant Phase 2 study topline data results anticipated in mid-2026.
• The VAX-31 Phase 3 non-inferiority study initiation for the adult indication is expected in mid-2025 with topline data in 2026.

Sentiment

Score: 8

Explanation: The document presents positive results from a Phase 2 study, indicating progress in Vaxcyte's vaccine development program. The announcement of a new vaccine candidate (VAX-XL) and plans for Phase 3 trials further contribute to a positive outlook.

Positives

• VAX-24 demonstrated a favorable safety profile similar to PCV20.
• VAX-24 elicited substantial immune responses, including IgG and OPA, across all doses.
• The mid-dose of VAX-24 met non-inferiority criteria for a significant number of serotypes.
• VAX-24 generated robust OPA responses, which are correlated with effectiveness against IPD.
• Unique serotypes in VAX-24 elicited robust immune responses.
• Dose-dependent immune responses were observed, indicating potential for optimization.
• Interim booster data showed robust memory responses.
• The company is advancing VAX-24 to a potential Phase 3 program.
• The company is developing VAX-XL, a third-generation PCV candidate, to further expand coverage.

Risks

• The initiation of the Phase 3 infant program is pending the VAX-31 Phase 2 study topline data readout, which is expected in mid-2026.
• The success of the Phase 3 program is subject to regulatory approvals and clinical trial outcomes.
• The development of VAX-XL is still in early stages and subject to development risks.

Future Outlook

Vaxcyte plans to initiate a Phase 3 infant program with either VAX-24 or VAX-31, pending the VAX-31 infant Phase 2 study topline data results anticipated in mid-2026. The VAX-31 Phase 3 non-inferiority study initiation for the adult indication is expected in mid-2025 with topline data in 2026.

Management Comments

• Grant Pickering, Chief Executive Officer and Co-Founder of Vaxcyte, stated that the results affirm the potential of their carrier-sparing platform to add coverage and maintain robust immune responses.
• Jim Wassil, Executive Vice President and Chief Operating Officer of Vaxcyte, emphasized the company's commitment to advancing the broadest-spectrum PCVs to address the substantial invasive pneumococcal disease burden in the infant population.

Industry Context

The announcement is relevant in the context of the pneumococcal vaccine market, where there is a need for broader-spectrum vaccines to address the evolving serotype landscape and antibiotic resistance. Vaxcyte is positioning itself to compete with established players like Pfizer and Merck by developing vaccines with broader coverage.

Comparison to Industry Standards

• The study compares VAX-24 to Prevnar 20 (PCV20), currently the broadest-spectrum PCV available, setting a high bar for performance.
• The company is aiming for non-inferiority to PCV20 for common serotypes and superior coverage with unique serotypes.
• The target Phase 2 IgG Geometric Mean Ratio (GMR) point estimate of >0.63 is based on the company's statistical analysis of precedent Phase 2 and Phase 3 studies, suggesting a data-driven approach to setting performance targets.
• Merck applied the >-15% for V114 (Vaxneuvance) Phase 2 endpoint supporting advancement to Phase 3.

Stakeholder Impact

• Shareholders: Positive results may lead to increased investor confidence.
• Patients: Successful development of VAX-24 and VAX-31 could provide broader protection against pneumococcal disease.
• Employees: Advancement to Phase 3 and development of new candidates may create opportunities for growth and development.

Next Steps

• The company will announce the balance of the VAX-24 Phase 2 dose-finding study data by the end of 2025.
• The company plans to initiate a Phase 3 infant program with either VAX-24 or VAX-31, pending the VAX-31 infant Phase 2 study topline data results anticipated in mid-2026.
• The company will initiate the VAX-31 Phase 3 non-inferiority study for the adult indication by mid-2025.

Key Dates

Keywords

VAX-24, VAX-31, Vaxcyte, pneumococcal conjugate vaccine, PCV, vaccine, immunogenicity, Phase 2 study, Phase 3 study, infants, Prevnar 20, VAX-XL, pneumococcal disease